Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
October 5–10, 1908 - The rapidly growing, global industry and scientific quest for absolute zero led to the 1st International Congress of Refrigeration held in Paris, France, at the Paris-Sorbonne University, which welcomed over 5,000 participants. January 25, 1909 - From this first Congress, the International Association of Refrigeration was born, formed by delegates from 35 countries. June 21, 1920 - The association was reorganised and officially titled as the International Institute of Refrigeration – IIR (Institut International du Froid – IIF, in French). IIR's status as an international organisation was defined by an International Agreement signed on December 1, 1954, and General Regulations for the Application of the International Agreements signed on November 20, 1956. Since then, the IIR has been operating at its headquarters based in Paris and is now an international organisation for expertise on refrigeration. The institute has continued to run the International Congress of Refrigeration every four years since its inauguration and has now expanded its event portfolio to ten conference series covering a wide variety of refrigeration topics. Working alongside governments, today the IIR remains committed to promoting knowledge on refrigeration for sustainable development, and continues to provide key services to disseminate information on associated technologies to all stakeholders (companies, universities, professionals, etc.).
== Creation == Their lineage dates back to include more than 200 years of unconventional warfare history, with notable predecessors including the American Revolutionary War "Swamp Fox" Francis Marion, Benjamin Forsyth in the War of 1812, Frederick Funston of the Philippine–American War, the WWII OSS Jedburgh Teams, OSS Detachment 101 in Burma, the Alamo Scouts, Colt Terry of the Korean War, and Vietnam War United States Army Special Forces officer Richard J. Meadows. Some of the Office of Strategic Services were similar in terms of the mission with the original U.S. Army Special Forces function, unconventional warfare (UW), acting as cadre to train and lead guerrillas in occupied countries. The Special Forces motto, De oppresso liber (Latin: "to free the oppressed") reflects this historical mission of guerrilla warfare against an occupying power. Specifically, the three-man Jedburgh teams provided leadership to French Resistance units. The larger Office of Strategic Services "OSS" Operational Groups (OG) were more associated with Strategic Reconnaissance/Direct Action (SR/DA) missions, although they did work with resistance units. Another unit widely associated with the origins of the Army Special Forces was the First Special Service Force, a joint Canadian-American unit formed in 1942 and disbanded in 1944. Members of the First Special Service Force were retroactively awarded the Special Forces Tab upon its creation in 1983 for their part in Special Forces' history.
However, many other acid-fast organisms—such as intestinal coccidia and parasitic helminths of the genus Schistosoma—lack mycolic acids yet display comparable acid-fastness, suggesting that other cell-wall structures, such as cyst walls or egg shells, may provide similar resistance to decolorization. Further histopathologic evidence supports this broader mechanism: in tissue sections, staining intensity is markedly reduced when bacterial cell walls are damaged or when xylene-based deparaffinization is used during specimen processing. A xylene-free, heat-based method has been shown to preserve cell-wall integrity and substantially improve detection of mycobacteria and other acid-fast organisms, particularly when using fluorescent Auramine O staining. Acid-fast organisms are difficult to characterize using standard microbiological techniques, though they can be stained using concentrated dyes, particularly when the staining process is combined with heat. Some, such as Mycobacteria, can be stained with the Gram stain, but they do not take the crystal violet well and thus appear light purple, which can still potentially result in an incorrect gram-negative identification. The most common staining technique used to identify acid-fast bacteria is the Ziehl–Neelsen stain, in which acid-fast species appear bright red against a blue background. Another method is the Kinyoun method, in which bacteria appear red against a green background.
=== Catabolic pathway (catabolism) === A catabolic pathway is a series of reactions that bring about a net release of energy in the form of a high energy phosphate bond formed with the energy carriers adenosine diphosphate (ADP) and guanosine diphosphate (GDP) to produce adenosine triphosphate (ATP) and guanosine triphosphate (GTP), respectively. The net reaction is, therefore, thermodynamically favorable, for it results in a lower free energy for the final products. A catabolic pathway is an exergonic system that produces chemical energy in the form of ATP, GTP, NADH, NADPH, FADH2, etc. from energy containing sources such as carbohydrates, fats, and proteins. The end products are often carbon dioxide, water, and ammonia. Coupled with an endergonic reaction of anabolism, the cell can synthesize new macromolecules using the original precursors of the anabolic pathway. An example of a coupled reaction is the phosphorylation of fructose-6-phosphate to form the intermediate fructose-1,6-bisphosphate by the enzyme phosphofructokinase accompanied by the hydrolysis of ATP in the pathway of glycolysis. The resulting chemical reaction within the metabolic pathway is highly thermodynamically favorable and, as a result, irreversible in the cell.
=== Laser therapy === Laser therapy is an approach that has been studied for treating hypertrophic scars. There is not enough evidence to determine if laser therapy is more effective than other treatments, or if laser therapy leads to more harm than benefit as compared to no treatment or different treatment.
Sources: en.wikipedia.org
=== Structural features === Animals have structural characteristics that set them apart from all other living things, such as cells being surrounded by an extracellular matrix composed of collagen and elastic glycoproteins, motility to spontaneously move their bodies during at least part of their life cycle, and a blastula stage during embryonic development. Typically, there is an internal digestive chamber with either one opening (in Ctenophora, Cnidaria, and flatworms) or two openings (in most bilaterians).
Thoracic outlet syndrome Arterial rupture Valvular heart disease, such as mitral valve prolapse, creates an increased risk for infective endocarditis during surgery. This may progress to a life-threatening degree. Heart conduction abnormalities have been found in those with hypermobility form of EDS. Dilation (aneurysm) or rupture (dissection) of ascending aorta Cardiovascular autonomic dysfunction such as postural orthostatic tachycardia syndrome Raynaud's phenomenon Varicose veins Heart murmur Heart conduction abnormalities
== Part 2 == The second part runs approximately two-and-a-half hours and follows Metallica at the start of their Wherever We May Roam Tour in Europe through to the Guns N' Roses/Metallica Stadium Tour of 1992. Included are performances of "For Whom the Bell Tolls" from Donington on August 17, 1991, "Enter Sandman" from the MTV Video Music Awards on September 5, "Harvester of Sorrow" from Moscow on September 28, "Sad but True" from the Day on the Green festival in Oakland, California on October 12, "Enter Sandman" from the Freddie Mercury Tribute Concert on April 20, 1992, and "Nothing Else Matters" from Phoenix on August 25. Jason Newsted after a concert in Portland, Maine, is seen making sandwiches to take back to a hotel with him instead of ordering room-service. His response to being called a cheapskate is "I got plans for those millions and it ain't for fucking sandwiches!" Sebastian Bach is seen joking with Slash and Lars Ulrich in Metallica's dressing room at RFK Stadium in Washington, D.C. prior to the opening concert of the joint tour with Guns N' Roses. Bach humorously imitates MTV host Riki Rachtman, and former Metallica guitarist Dave Mustaine. The band also encounter Spinal Tap, who jokingly ask them about the similarities between their album's covers. This part of the documentary also includes two music videos:
Ranirestat (also known as AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy by Dainippon Sumitomo Pharma and PharmaKyorin. It has been granted orphan drug status. The drug is to be used orally.
Iranian support for the Houthis List of military units named after people Red Sea crisis – Houthi involvement in the Gaza war Timeline of the Yemeni crisis (2011–present) Outline of the Yemeni crisis, revolution, and civil war (2011–present) Muhammad Abd al-Karim al-Ghamari
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.